Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387853 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT02387853 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 117 participants.
The verdict
NCT02387853, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.
Interventions
- DRUG LEO 90100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02387853
The ClinicalTrials.gov registry entry for NCT02387853 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LEO 90100 is the first listed.
NCT02387853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02387853 about?
NCT02387853 is a clinical study titled "Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis". An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.
What is the current status of trial NCT02387853?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2016-03. Estimated completion is 2018-03-28.
What interventions are being tested in trial NCT02387853?
The interventions under investigation include: LEO 90100 (DRUG).
Who is sponsoring clinical trial NCT02387853?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.